metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Pilot study: management with pentoxifylline in patients with chronic liver disea...
Información de la revista
Vol. 27. Núm. S3.
Abstracts from XVII Mexican Congress of Hepatology
(diciembre 2022)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 27. Núm. S3.
Abstracts from XVII Mexican Congress of Hepatology
(diciembre 2022)
Open Access
Pilot study: management with pentoxifylline in patients with chronic liver disease and COVID-19
Visitas
334
MA Jiménez-Luévano, AE Jiménez-Partida, MA Jiménez-Partida, A Bravo-Cuellar, Y Cortes-Aguilar
Regional Hospital “Dr. Valentín Gómez Farías”. Gastroenterology Service. ISSSTE. Mexico
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Suplemento especial
Este artículo forma parte de:
Vol. 27. Núm S3

Abstracts from XVII Mexican Congress of Hepatology

Más datos
Introduction and Objectives

This study aimed to improve the response to adjuvant treatment with pentoxifylline in patients with SARS-CoV-2 and previous chronic liver disease.

Materials and Methods

In the ISSSTE hospital of Zapopan for eight months, 51 patients with moderate to severe SARS-CoV-2 and chronic liver disease, 26 with cirrhosis and 25 with steatohepatitis were evaluated, with prior informed consent and endorsed by the ethics committee. They were administered pentoxifylline 400 mg for 28 days, in addition to supportive measures such as paracetamol 750 mg, celecoxib 100 mg, or anticoagulants (enoxaparin) in patients with D-dimer > 600 mg/dL and supplemental oxygen in patients with saturation < 90. Clinical, laboratory and mortality variables were analyzed. The trial was approved by the research ethics committee, and informed consent was obtained.

Results

They were patients with Covid-19 plus cirrhosis and steatohepatitis. They survived 100%, after 28 days of driving, in addition to avoiding admission to intensive care.

Discussion

Pentoxifylline is a methylxanthine with antioxidant, hemorheological, anti-inflammatory and immunomodulatory properties since it inhibits NF-KB (via JAK/STAT and 1KB), pro-inflammatory cytokines, phosphodiesterase, in addition to stimulating anti-inflammatory cytokines, interferon-gamma, growth factors, TGF beta and granulocyte growth factor. Also, antiviral, as in Japanese encephalitis virus, vaccine virus, Rotavirus, HPV, respiratory syncytial virus, HIV, HCV, etc.

Conclusions

This viremia is severe in vulnerable groups, particularly liver diseases. It is inferred that Pentoxifylline may be alternative management, as manifested in this group of patients who managed to survive. So, we suggest multicenter and randomized studies to know their real benefit.

Funding

The resources used in this study were from the hospital without any additional financing

Declaration of interest

The authors declare no potential conflicts of interest.

Texto completo

Table 1. Demographic, biochemical and symptomatology characteristics of the two groups

Previous pathologies  Steatohepatitis  Liver cirrhosis 
Age  55.64  60,84 
Gender  72% women - 28% men  42% women – 58% men 
BMI  30.76  27.84 
Comorbidities     
Overweight / obesity  100%  100% 
DM 2  31%  20% 
Alcoholism  0%  27% 
Autoimmune disease  0%  4% 
Laboratory     
AST  42.24  56.76 
ALT  50.25  69.90 
DHL  308.2  315.6 
Platelets  170  100.38 
Ferritin  496.24  592.5 
D-dimer  530.54  1,064 
Lymphocytes  35.2  29.96 
ESR  32.32  30.06 
PCR  49  47.03 
Oxygen saturation  85.24  85.69 
Clinic:     
Cough  16 (64%)  14 (54%) 
Dyspnea  13 (52%)  12 (46%) 
Pneumonia  5 (20%)  8 (32%) 
Asthenia  6 (24%)  6 (24%) 
Fever  2 (8%)  13 (52%) 
Headache  3 (12%)  8 (31%) 
Anosmia  1 (4%)  1 (4%) 
Shivers  1 (4%)  1 (4%) 
Arthralgia  3 (12%)  2 (8%) 
Diarrhea  1 (4%)  2 (8%) 

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2022.100837
No mostrar más